Thromb Haemost 2017; 117(08): 1471-1477
DOI: 10.1160/TH16-11-0880
Coagulation and Fibrinolysis
Schattauer GmbH

Low plasma FVII:C and activated FVII as predictive markers for overt disseminated intravascular coagulation

Surapong Lertthammakiat
1   Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
,
Nattachai Anantasit
1   Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
,
Usanarat Anurathapan
1   Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
,
Nongnuch Sirachainan
1   Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
,
Praguywan Kadegasem
1   Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
,
Ampaiwan Chuansumrit
1   Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
› Author Affiliations
Financial support: This study was supported by a grant from the Faculty of Medicine Ramathibodi Hospital and Thai Society of Hematology.
Further Information

Publication History

Received: 23 November 2016

Accepted after major revision: 14 April 2017

Publication Date:
22 November 2017 (online)

Summary

In sepsis, binding of factor VII (FVII:C) and activated factor VII (FVIIa) with tissue factor is the key step of coagulation resulting in disseminated intravascular coagulation (DIC). We conducted a prospective cohort study among 47 septic patients, aged 8 months to 18.8 years. They were initially divided into three groups of no DIC (n=27), non-overt DIC (n=14) and overt DIC (n=6). Blood samples were collected at 0, 24 and 48 hours (h) after the onset of sepsis. At the onset of sepsis, FVII:C tended to be lower in the non-overt DIC [median 57% (interquartile range [IQR] 41–80)] and overt DIC groups [33% (23–52)] than that in the no DIC group [65% (44–87)]. Whereas FVIIa tended to be lower in the overt DIC group [1.29% (0.50–4.19)] than those in the non-overt DIC [3.01% (1.01–5.24)] and no DIC groups [2.49% (1.14–3.13)]. At 24 h, FVII:C was significantly lower in the non-overt DIC [57% (41–101)] and overt DIC groups [31% (28–49)] than that in the no DIC group [83% (70–102)]. While FVIIa was significantly lower in the overt DIC group [2.15% (0.86–3.96)] than that in the no DIC group [3.83% (2.90–5.46)]. Using FVII:C <65% or FVIIa <3% at 24 h among patients without hepatic dysfunction to determine overt DIC at 24 h, the sensitivity was 83.9% and 77.4%, respectively, and the specificity was both 83.3%. Patients with low FVII:C and low FVIIa at 24 h after the onset of sepsis had a 20.8-fold (95% confidence interval [CI], 2.0–213.0, p=0.010) and 14.4-fold (95%CI, 1.5–142.4, p=0.023) chance of overt DIC.

 
  • References

  • 1 Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J 2006; 04: 4.
  • 2 Toh CH, Alhamdi Y. Current consideration and management of disseminated intravascular coagulation. Hematology Am Soc Hematol Educ Program 2013 2013; 286-291.
  • 3 Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care 2014; 02: 20.
  • 4 Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care 2014; 02: 15.
  • 5 Wildgoose P, Nemerson Y, Hansen LL. et al. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-28.
  • 6 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744.
  • 7 Rao VL, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-6691.
  • 8 Takahashi H, Satoh N, Wada K. et al. Tissue factor in plasma of patients with disseminated intravascular coagulation. Am J Hematol 1994; 46: 333-7.
  • 9 Asakura H, Kamikubo Y, Goto A. et al. Role of tissue factor in disseminated intravascular coagulation. Thromb Res 1995; 80: 217-224.
  • 10 Shimura M, Wada H, Wakita Y. et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1997; 55: 169-174.
  • 11 Østerud B, BjØrklid E. Tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 605-617.
  • 12 Orkin SH, Fisher DE, Ginsburg D. et al. Blood coagulation. In: Nathan and Oski's hematology and oncology of infancy and childhood. 8th ed.. Philadelphia, PA: Elsevier Saunders; 2015: 964-983.
  • 13 Scarabin PY, Vissac AM, Kirzin JM. et al. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol 1996; 16: 1770-1776.
  • 14 Karatela RA, Sainani GS. Interrelationships of factor VII activity and plasma leptin with insulin resistance in coronary heart disease. Atherosclerosis 2010; 209: 235-240.
  • 15 Turfan M, Poyraz F, Kaymak AO. et al. Plasma levels and distribution of gene polymorphisms of factor VII in Turkish population. Clin Appl Thromb Hemost 2014; 20: 164-168.
  • 16 Gentile NT, Vaidyula VR, Kanamalla U. et al. Factor VIIa and tissue factor pro-coagulant activity in diabetes mellitus after acute ischemia stroke: impact of hyperglycemia. Thromb Haemost 2007; 98: 1007-1013.
  • 17 Karatela RA, Sainani GS. Interrelationship between coagulation factor VII and obesity in diabetes mellitus (type 2). Diabetes Res Clin Pract 2009; 84: e41-44.
  • 18 Quek SC, Low PS, Saha N, Heng CK. The effects of three factor VII polymorphisms on factor VII coagulant levels in healthy Singaporean Chinese, Malay and Indian newborns. Ann Hum Genet 2006; 70: 951-957.
  • 19 Lopaciuk S, Windyga J, Watala CW, Bykowska K, Pietrucha T, Kwiecinski H. et al. Polymorphisms in the factor VII gene and ischemic stroke in young adults. Blood Coagul Fibrinolysis 2010; 21: 442-447.
  • 20 Zakai NA, Lange L, Longstreth Jr WT. et al. Association of coagulation and inflammation related genes and factor VIIc levels with stroke: the Cardiovascular Health Study. Thromb Haemost 2011; 09: 267-274.
  • 21 Green G, Poller L, Thomsen JM, Dymock IW, Factor VII. as a marker of hepatocellular synthetic function in liver disease. J Clin Pathol 1976; 29: 971-975.
  • 22 Rodríguez-Iñigo E, Bartolomé J, Quiroga JA. et al. Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasis. Blood Coagul Fibrinolysis 2001; 12: 193-199.
  • 23 Branchini A, Rizzotto L, Mariani G. et al. Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency. Haematologica 2012; 97: 705-709.
  • 24 Kario K, Matsuo T, Yamamoto K, Kobayashi H. Plasma factor VII levels in disseminated intravascular coagulation. Rinsho Byori 1991; 39: 683-688.
  • 25 Biron C, Bengler C, Gris JC, Schved JF. Acquired isolated factor VII deficiency during sepsis. Haemostasis 1997; 27: 51-56.
  • 26 Collins PW, Macchiavello LI, Lewis SJ. et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 2006; 135: 220-227.
  • 27 Mesters RM, Mannucci PM, Coppola R. et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88: 881-886.
  • 28 Yamada A, Wada H, Kamikura Y. et al. Plasma levels of activated factor VII in various diseases. Blood Coagul Fibrinolysis 1996; 07: 794-798.
  • 29 Hyseni A, Kemperman H, de Lange DW. et al. Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa. Thromb Haemost 2013; 11: 2111-2117.
  • 30 Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 06: 2-8.
  • 31 Dellinger RP, Levy MM, Rhodes A. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637.
  • 32 Taylor Jr FB, Toh CH, Hoots WK. et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-1330.
  • 33 Leteurtre S, Duhamel A, Salleron J. et al. PELOD-2: an update of the pediatric logistic organ dysfunction score. Crit Care Med 2013; 41: 1761-1773.
  • 34 Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated pediatric risk of mortality score. Crit Care Med 1996; 24: 743-752.
  • 35 Hellstern P, Beeck H, Fellhauer A. et al. Measurement of factor VII and of activated factor VII in healthy individuals and in prothrombin complex concentrates. Thromb Res 1997; 86: 493-504.
  • 36 Chuansumrit A, Hotrakitya S, Sirinavin S. et al. Disseminated intravascular coagulation findings in 100 patients. J Med Assoc Thai 1999; 82: 63-68.
  • 37 Kushimoto S, Gando S, Saitoh D. et al. Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine Criteria. Comparison between sepsis and trauma. Thromb Haemost 2008; 100: 1099-1105.
  • 38 Mahanupap P, Angchaisuksiri P, Rattanasiri S. Disseminated intravascular coagulation in Ramathibodi Hospital. J Hematol Transfus Med 2010; 20: 27-37.
  • 39 Rey C, Arcos ML, Concha A. et al. Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children. Intensive Care Med 2007; 33: 477-484.
  • 40 Adcock D, Kressin D, Marlar RA. The effect of time and temperature variables on routine coagulation tests. Blood Coagul Fibrinolysis 1998; 09: 463-470.
  • 41 Awad MA, Selim TE, Al-Sabbagh FA. Influence of storage time and temperature on international normalized ratio (INR) levels and plasma activities of vitamin K dependent clotting factors. Hematology 2004; 09: 333-337.